Pages that link to "Q407431"
Jump to navigation
Jump to search
The following pages link to (RS)-warfarin (Q407431):
Displayed 50 items.
- aspirin (Q18216) (← links)
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- 4-Hydroxycoumarins (Q3599051) (← links)
- New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons (Q21132464) (← links)
- Vitamin K epoxide reductase complex subunit 1 (Q21175110) (← links)
- warfarin exposure (Q21175420) (← links)
- Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups (Q21284803) (← links)
- NIOSH Method 5002: Warfarin (Q21761712) (← links)
- Exposures to pharmaceutical dust at a mail order pharmacy (Q23916127) (← links)
- Warfarin initiation nomograms for venous thromboembolism (Q24186324) (← links)
- New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease (Q24192938) (← links)
- Vitamin K for improved anticoagulation control in patients receiving warfarin (Q24194649) (← links)
- Warfarin initiation nomograms for venous thromboembolism (Q24201274) (← links)
- Optimal loading dose of warfarin for the initiation of oral anticoagulation (Q24202077) (← links)
- Vitamin K for improved anticoagulation control in patients receiving warfarin (Q24202915) (← links)
- Optimal loading dose of warfarin for the initiation of oral anticoagulation (Q24236138) (← links)
- Warfarin initiation nomograms for venous thromboembolism (Q24240381) (← links)
- Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin (Q24293609) (← links)
- Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients (Q24307602) (← links)
- Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction (Q24311573) (← links)
- A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy (Q24314592) (← links)
- CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant (Q24322624) (← links)
- Warfarin interaction with Matricaria chamomilla (Q24542494) (← links)
- Possible interaction between warfarin and cranberry juice (Q24623457) (← links)
- Cardiac tamponade secondary to haemopericardium in a patient on warfarin (Q24642911) (← links)
- Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding (Q24647605) (← links)
- Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study (Q24658646) (← links)
- Warfarin reversal (Q24672566) (← links)
- Warfarin: almost 60 years old and still causing problems (Q24678632) (← links)
- Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (Q24678775) (← links)
- Drug interactions with warfarin: what clinicians need to know (Q24681312) (← links)
- Health hazard evaluation report: evaluation of safety climate, health concerns, and pharmaceutical dust exposures at a mail order pharmacy (Q24706840) (← links)
- The use of warfarin in veterans with atrial fibrillation (Q24793600) (← links)
- Patients' perspectives on taking warfarin: qualitative study in family practice (Q24798132) (← links)
- Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study, Etc. (Q24801915) (← links)
- Health hazard evaluation report: HETA-2010-0026-3150, exposures to pharmaceutical dust at a mail order pharmacy - Illinois (Q24851922) (← links)
- Warfarin resistance (Q24975519) (← links)
- Pharmacogenomics and individualized medicine (Q26250236) (← links)
- Failure Report No. S307 (Q26377983) (← links)
- Clinical Question: In adult patients on warfarin, does-home-self-testing of prothrombin time and/or international normalized ratio provide the same outcomes compared to testing by a home health nurse or in a clinical setting? (Q26748658) (← links)
- Novel oral anticoagulants and the 73rd anniversary of historical warfarin (Q26771544) (← links)
- How to manage warfarin therapy (Q26773328) (← links)
- Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants (Q26781181) (← links)
- Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? (Q26823542) (← links)
- Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? (Q26826007) (← links)
- Spontaneous lingual and sublingual haematoma: a rare complication of warfarin use (Q26829379) (← links)
- Risk-benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis (Q26999056) (← links)
- Management of patients who are receiving warfarin or a new oral anticoagulant and require urgent or emergency surgery (Q27000446) (← links)
- Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis (Q27002899) (← links)
- Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon (Q27006860) (← links)